---
title: "daepoch-r"
slug: "daepoch-r"
date: "2024-05-02"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[regimen-of-management_of_diffuse_large_b-cell_lymphoma]]

# daepoch-r

1.Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology. 2018;5(12):e609-e617. doi:10.1016/S2352-3026(18)30177-7

- **Design:** Phase III trial
- **Number of patients:** 491
- **Patients characteristics:** Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5
- **Agent:**
  - Intervention: DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
  - Control: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
- **Treatment line:** Frontline therapy for diffuse large B-cell lymphoma
- **Trial Acronym or NCTId Number:** Alliance/CALGB 50303 (NCT00118209)
- **Comparison of outcomes:**

  | 2y Outcome                | DA-EPOCH-R   | R-CHOP       |
  | ------------------------- | ------------ | ------------ |
  | Progression-free Survival | 78.9%        | 75.5%        |
  | Overall Survival          | 86.5%        | 85.7%        |
  | Response Rate             | not reported | not reported |
